This FTSE 250 stock looks too cheap 

A dividend yielding over 5% and earnings growth ahead means this FTSE 250 stock might have been oversold in the bear market.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Hand of person putting wood cube block with word VALUE on wooden table

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There doesn’t seem to be much wrong with the Inchcape (LSE: INCH) business but the FTSE 250 stock has been punished by the market lately.

The international automotive distributor’s share price is near 665p, meaning it’s down around 28% since January 2023.

Despite the stock’s weak performance, the company’s earnings have been trending higher. And on 26 October 2023, the company reported robust third-quarter results.

Strong recent business performance

Chief executive Duncan Tait said performance was strong in all operational geographies.

Looking ahead, Tait thinks the highly cash-generative and capital-light characteristics of the business will help keep the positive momentum going in the coming years. And Inchcape’s strategy aims to continue consolidating a “highly fragmented” market through growth and acquisitions.

City analysts expect earnings to increase by about 21% in 2023. And they anticipate a further advance of around 10% in 2024. Meanwhile, the directors “remain confident” about the medium- to long-term outlook for the business.

Those figures and expectations look pretty strong, to me. So, it’s a bit of a surprise to see what seems like a low valuation.

The forward-looking earnings multiple for 2024 is just over seven. And the anticipated dividend yield is about 5.6%.

Those indicators make the company look too cheap. However, it’s worth considering the balance sheet. Net debt is near £1bn. And that compares to a market capitalisation of around £2.7bn.

I’d consider the company as being on a multiple closer to 10 than seven when factoring in the debt load.

Acquisitive businesses often carry some debt and that situation introduces risk for shareholders. It’s worth keeping an eye on borrowings to make sure they don’t start to get out of control.

But for now, the interest cover from earnings is running just above five. And that’s okay as long as profits and cash flows hold up in the future.

Cyclical sensitivity

However, the multi-year financial and trading record shows the business has cyclical vulnerabilities. Inchcape was one of those firms that suffered when the pandemic hit. And its earnings plunged, as we might expect.

The directors reduced the dividends back then, but they’ve come storming back since. Nevertheless, fears of general economic weakness ahead could be one of the factors weighing on the share price and the valuation now. And a worldwide downturn is indeed another risk that investors must face up to with Inchcape shares.

However, I see the positive third-quarter update as encouraging. And the valuation is attractive.

My data provider shows that all the City analysts commenting on the company have the stock marked as either a ‘buy’ or a ‘strong buy’. And, on balance, I agree and think Inchcape is worth investors’ further research time now.  Perhaps the shares could make a worthwhile addition to a long-term diversified portfolio.

Kevin Godbold has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Close-up of British bank notes
Investing Articles

£20,000 for a Stocks and Shares ISA? Here’s how to try and turn it into a monthly passive income of £493

Hundreds of pounds in passive income a month from a £20k Stocks and Shares ISA? Here's how that might work…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

£5,000 put into Nvidia stock last Christmas is already worth this much!

A year ago, Nvidia stock was already riding high -- but it's gained value since. Our writer explores why and…

Read more »

Investing Articles

Are Tesco shares easy money heading into 2026?

The supermarket industry is known for low margins and intense competition. But analysts are bullish on Tesco shares – and…

Read more »

Smiling black woman showing e-ticket on smartphone to white male attendant at airport
Investing Articles

Can this airline stock beat the FTSE 100 again in 2026?

After outperforming the FTSE 100 in 2025, International Consolidated Airlines Group has a promising plan to make its business more…

Read more »

Investing Articles

1 Stocks and Shares ISA mistake that will make me a better investor in 2026

All investors make mistakes. The best ones learn from them. That’s Stephen Wright’s plan to maximise returns from his Stocks…

Read more »

Portrait Of Senior Couple Climbing Hill On Hike Through Countryside In Lake District UK Together
Investing Articles

I asked ChatGPT if £20,000 would work harder in an ISA or SIPP in 2026 and it said…

Investors have two tax-efficient ways to build wealth, either in a Stocks and Shares ISA or SIPP. Harvey Jones asked…

Read more »

Investing Articles

How much would I need invested in an ISA to earn £2,417 a month in passive income?

This writer runs the numbers to see what it takes in an ISA to reach £2,417 a month in passive…

Read more »

Investing Articles

Rolls-Royce shares or Melrose Industries: Which one is better value for 2026?

Rolls-Royce shares surged in 2025, surpassing most expectations. Dr James Fox considers whether it offers better value than peer Melrose.

Read more »